复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

午间休市 01-23 12:05:00

20.520

+0.280

+1.38%

最高20.860	最低20.440	成交量128.10万
今开20.500	昨收20.240	日振幅2.08%
总市值545.63亿	流通市值111.01亿	总股本26.59亿
成交额2,642万	换手率0.24%	流通股本5.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":20.52,"timestamp":1769141100004,"preClose":20.24,"halted":0,"volume":1281000,"delay":0,"changeRate":0.013833992094861717,"floatShares":540971500,"shares":2659000000,"eps":1.1622573996506331,"marketStatus":"午间休市","change":0.28,"latestTime":"01-23 12:05:00","open":20.5,"high":20.86,"low":20.44,"amount":26419833,"amplitude":0.020751,"askPrice":20.54,"askSize":5000,"bidPrice":20.52,"bidSize":11000,"shortable":3,"etf":0,"ttmEps":1.3870127278994322,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1769144400000},"marketStatusCode":3,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":20.24,"dividendRate":0.017486,"openAndCloseTimeList":[[1769131800000,1769140800000],[1769144400000,1769155200000]],"volumeRatio":0.952479,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":27.53,"timestamp":1769138998000,"preClose":27.25,"halted":0,"volume":13171300,"delay":0,"premium":"-33.48"}},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"2605491866","title":"复星医药：近年来公司持续在创新研发等多维度践行国际化战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2605491866","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605491866?lang=zh_cn&edition=full","pubTime":"2026-01-22 21:03","pubTimestamp":1769087023,"startTime":"0","endTime":"0","summary":"证券日报网讯1月22日，复星医药在互动平台回答投资者提问时表示，近年来，公司持续在创新研发、许可引进、生产运营及商业化等多维度践行国际化战略，提升运营效率，强化全球市场布局，并已主要覆盖美国、欧洲、非洲、印度和东南亚等海外市场。公司在欧盟市场的销售模式采用了多元化方式。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627658039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK0196","BK0028","BK0183","BK0239","BK0012","BK0188","600196","BK0060","BK0175","BK0187","02196","BK1191","BK1593","BK0096"],"gpt_icon":0},{"id":"2605462947","title":"复星医药最新公告：分拆所属子公司复星安特金至香港联交所主板上市获董事会批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2605462947","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605462947?lang=zh_cn&edition=full","pubTime":"2026-01-22 18:10","pubTimestamp":1769076641,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司第十届董事会第二十二次会议审议通过关于分拆所属子公司复星安特金（成都）生物制药股份有限公司至香港联交所主板上市的议案。该议案包括分拆上市符合相关法律法规规定、首次公开发行H股股票方案、分拆上市预案以及分拆上市符合《上市公司分拆规则（试行）》等内容。公司表示，本次分拆上市符合相关法律法规及监管机构的要求，具备可行性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200030530.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02196","BK0096","BK0028","BK0060","BK1191","BK0187","BK1593","BK0012","BK0175","BK0196","BK0239","BK1515","BK0188","BK0183","600196"],"gpt_icon":0},{"id":"2605462911","title":"复星医药最新公告：控股子公司药品重酒石酸去甲肾上腺素注射液获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2605462911","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605462911?lang=zh_cn&edition=full","pubTime":"2026-01-22 18:09","pubTimestamp":1769076585,"startTime":"0","endTime":"0","summary":"复星医药公告称，公司控股子公司锦州奥鸿药业有限责任公司就重酒石酸去甲肾上腺素注射液的药品注册申请获国家药品监督管理局批准。该药品获批适应症包括急性低血压状态的血压恢复、心跳骤停的辅助治疗和心跳骤停复苏后的血压维持等。该药品为复星医药自主研发的化学药品，截至2025年12月，累计研发投入约为人民币874万元。该药品获批上市将进一步丰富复星医药的产品线，但具体销售情况可能受到多种因素影响，具有较大不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200030532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0012","BK0175","BK0196","BK1515","BK0060","BK1191","02196","BK1593","BK0239","BK0096","BK0188","600196","BK0028","BK0183"],"gpt_icon":0},{"id":"2605746108","title":"复星医药01月21日主力净流入146.2万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2605746108","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605746108?lang=zh_cn&edition=full","pubTime":"2026-01-21 16:15","pubTimestamp":1768983337,"startTime":"0","endTime":"0","summary":"01月21日, 复星医药股价涨0.89%，报收20.44元，成交金额7307.5万元，换手率0.67%，振幅1.68%，量比1.08。复星医药今日主力资金净流入146.2万元，上一交易日主力净流出80.6万元。该股近5个交易日下跌5.80%，主力资金累计净流出651.5万元；近20日主力资金累计净流入380.5万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121162714a69b68f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121162714a69b68f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1191","BK1593","BK1515"],"gpt_icon":0},{"id":"2604119589","title":"复星医药：控股子公司药品获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2604119589","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604119589?lang=zh_cn&edition=full","pubTime":"2026-01-20 16:55","pubTimestamp":1768899334,"startTime":"0","endTime":"0","summary":"人民财讯1月20日电，复星医药(600196)1月20日公告，控股子公司复宏汉霖收到国家药品监督管理局关于同意HLX701（重组人SIRPα-IgG4Fc融合蛋白注射液）联合西妥昔单抗和化疗治疗晚期结直肠癌开展Ⅰb/Ⅱ期临床试验的批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601203624726698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK0096","BK0175","BK0183","BK1191","600196","BK1593","BK0012","BK0187","BK0239","BK0188","BK0028","BK0060","BK0196","02196"],"gpt_icon":0},{"id":"2604184161","title":"复星医药（600196）披露控股子公司部分境内未上市股份申请全流通完成中国证监会备案，01月19日股价下跌0.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604184161","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604184161?lang=zh_cn&edition=full","pubTime":"2026-01-19 17:29","pubTimestamp":1768814961,"startTime":"0","endTime":"0","summary":"截至2026年1月19日收盘，复星医药报收于27.44元，较前一交易日下跌0.54%，最新总市值为732.77亿元。近日，复星医药发布关于控股子公司部分境内未上市股份申请全流通完成中国证监会备案的公告。公告称，公司控股子公司复宏汉霖若干股东合计持有的182,645,856股境内未上市股份转为H股并在香港联交所上市的申请已完成中国证监会备案。其中，复星医药控股子公司复星新药持有的120,000,000股非上市股可转换为H股。复星医药表示目前无减持复宏汉霖股份的计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900023508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0187","BK1593","02196","BK0188","BK0183","600196","BK0239","BK0196","BK0060","BK0175","BK1191","BK0096","BK1515"],"gpt_icon":0},{"id":"2603969492","title":"复星医药：控股子公司复宏汉霖若干名股东合计持有的1.83亿股复宏汉霖境内未上市股份转为境外上市股份并于香港联交所上市流通的申请事项，已完成中国证监会备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2603969492","media":"国际金融报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603969492?lang=zh_cn&edition=full","pubTime":"2026-01-16 17:05","pubTimestamp":1768554310,"startTime":"0","endTime":"0","summary":"复星医药公告，控股子公司复宏汉霖若干名股东合计持有的1.83亿股复宏汉霖境内未上市股份转为境外上市股份(即H股)并于香港联交所上市流通的申请事项，已完成中国证监会备案。其中，本公司控股子公司复星新药持有的1.2亿股复宏汉霖非上市股可转换为H股。如该等股份全数获转换后，本公司通过若干控股子公司合计所持有复宏汉霖股份总数保持不变，其中H股1.52亿股、非上市股1.92亿股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116170610a4cb5945&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116170610a4cb5945&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","HK0000306685.HKD","HK0000165453.HKD","HK0000320223.HKD","BK1161","BK1593","HK0000320264.USD","HK0000306701.USD","02196","BK1191","BK1515"],"gpt_icon":0},{"id":"2603626967","title":"【券商聚焦】交银国际：JPM医药大会有望继续催化板块行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2603626967","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603626967?lang=zh_cn&edition=full","pubTime":"2026-01-15 09:09","pubTimestamp":1768439355,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际发布医药行业周报，本周26省联盟药品集采开启，纳入多项国采可替代品种，该机构认为具备成本与渠道优势的头部企业将获益；同时两大进口主导型耗材省际联盟集采启动，国产替代进程有望进一步提速。JPM医药大会将于本周召开，超20家中国公司将出席并发表主题演讲，有望继续催化行情。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973261","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","BK4581","02268","IE00B5MMRT66.SGD","LU2211815571.USD","SG9999004311.SGD","BK1515","LU0820561909.HKD","LU1496350171.SGD","01789","LU0307460666.USD","BK1197","LU0868494617.USD","LU0310799852.SGD","LU0345770308.USD","LU1670628061.USD","LU1116320737.USD","LU0496365809.HKD","LU1988902786.USD","01530","09939","BK1141","IE00BN8TJ469.HKD","02367","03933","03329","LU2430703095.HKD","LU0238689110.USD","159938","LU0267386448.USD","LU1719994722.HKD","LU2357305700.SGD","01099","LU0942090050.USD","LU1032466523.USD","LU0211327993.USD","06160","IE00BWXC8680.SGD","LU2592432038.USD","LU0215105999.USD","BK4207","LU1064131342.USD","LU1280957306.USD","02196","09926","LU0640798160.USD","LU2505996681.GBP","BK1593"],"gpt_icon":0},{"id":"2603561455","title":"复星医药（600196）公司公告控股子公司激励计划实施进展，1月14日股价下跌0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603561455","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603561455?lang=zh_cn&edition=full","pubTime":"2026-01-14 22:09","pubTimestamp":1768399757,"startTime":"0","endTime":"0","summary":"截至2026年1月14日收盘，复星医药报收于28.07元，较前一交易日下跌0.39%，最新总市值为749.59亿元。近日，复星医药发布关于控股子公司激励计划实施进展的公告。公告显示，其控股子公司复星安特金首期激励计划获修订，激励工具由期权变更为限制性股权，并设置分四期解锁条件，每期解锁比例上限为25%。2026年1月14日，复星安特金董事会确认存续有效的限制性股权为2,440,293份，对应注册资本244.0293万元，占总注册资本约2.9356%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400040959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0060","BK0183","BK0188","BK0187","BK0028","BK1191","BK1515","02196","BK1593","BK0196","BK0239","BK0096","600196","BK0012"],"gpt_icon":0},{"id":"2603469483","title":"复星医药子公司注射用乳糖酸红霉素注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2603469483","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603469483?lang=zh_cn&edition=full","pubTime":"2026-01-14 17:55","pubTimestamp":1768384537,"startTime":"0","endTime":"0","summary":"北京商报讯1月14日，复星医药发布公告称，公司控股子公司苏州二叶制药有限公司就注射用乳糖酸红霉素的药品注册申请于近期获国家药品监督管理局受理，拟用于治疗由特定微生物敏感株引起的感染、预防风湿热初发、预防风湿热复发以及预防细菌性心内膜炎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601143619068536.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601143619068536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK0060","BK1515","BK0188","BK0183","02196","BK0096","BK1593","BK1191","BK0175","BK0187","BK0196","BK0028","BK0012","600196"],"gpt_icon":0},{"id":"2603205694","title":"复星医药控股子公司复星凯瑞与思比曼生物宣布就AlloJoin 干细胞疗法达成商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2603205694","media":"复星医药官微","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603205694?lang=zh_cn&edition=full","pubTime":"2026-01-14 17:22","pubTimestamp":1768382542,"startTime":"0","endTime":"0","summary":"1月14日，复星医药控股子公司复星凯瑞正式宣布，通过战略合作获得思比曼生物科技ElpasBio Holdings异体人源脂肪间充质干细胞注射液洛它阿托赛在中国境内及港澳地区的独家商业化权益。基于复星凯瑞在细胞治疗领域的商业化能力和洞察，思比曼生物授予复星凯瑞AlloJoin 在中国境内及港澳地区的独家商业化权益。核心产品AlloJoin 是中国首个获批进入III期临床试验的治疗膝骨关节炎的干细胞药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114174744a4c2b73e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114174744a4c2b73e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1515","00656","BK1230","BK1191","02196"],"gpt_icon":0},{"id":"2603390596","title":"每日卖空追踪 | 复星医药 01月13日卖空量成交41.9万股，卖空比例为5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603390596","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603390596?lang=zh_cn&edition=full","pubTime":"2026-01-13 16:30","pubTimestamp":1768293028,"startTime":"0","endTime":"0","summary":"复星医药北京时间01月13日，涨4%，卖空量成交41.9万股，较上一交易日增加14.48%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113165300a7150641&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113165300a7150641&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1515","BK1191","BK1593"],"gpt_icon":0},{"id":"2603639093","title":"复星医药、中汇人寿等在天津成立股权投资基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2603639093","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603639093?lang=zh_cn&edition=full","pubTime":"2026-01-13 15:39","pubTimestamp":1768289940,"startTime":"0","endTime":"0","summary":"21财经1月13日电，天眼查工商信息显示，近日，中汇复弘（天津）股权投资基金合伙企业（有限合伙）成立，执行事务合伙人为弘毅私募基金管理（天津）合伙企业（有限合伙），出资额5.47亿人民币，经营范围为以私募基金从事股权投资、投资管理、资产管理等活动。合伙人信息显示，该基金由中汇人寿保险股份有限公司、上海复星医药产业发展有限公司、弘毅私募基金管理（天津）合伙企业（有限合伙）共同出资。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113154047a4bdc71a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113154047a4bdc71a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1515","BK1191","BK1593"],"gpt_icon":0},{"id":"2603639707","title":"复星医药盘中异动 大幅上涨5.04%报22.080港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603639707","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603639707?lang=zh_cn&edition=full","pubTime":"2026-01-13 09:57","pubTimestamp":1768269426,"startTime":"0","endTime":"0","summary":"2026年01月13日早盘09时57分，复星医药股票出现波动，股价大幅上涨5.04%。截至发稿，该股报22.080港元/股，成交量189.11万股，换手率0.35%，振幅4.66%。资金方面，该股资金流入2608.13万港元，流出807.244万港元。复星医药股票所在的药品行业中，整体涨幅为1.15%。其相关个股中，三生制药、康龙化成、复星医药涨幅较大，振幅较大的相关个股有华控康泰、君圣泰医药-B、康龙化成，振幅分别为10.00%、7.19%、6.35%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011309570697a1887c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011309570697a1887c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1593","BK1515","02196"],"gpt_icon":0},{"id":"1137978914","title":"港股创新药概念股盘初普涨！乐普生物-B涨超8%，药明康德涨超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1137978914","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137978914?lang=zh_cn&edition=full","pubTime":"2026-01-13 09:45","pubTimestamp":1768268737,"startTime":"0","endTime":"0","summary":"1月13日，港股创新药概念股盘初普涨，$乐普生物-B(02157)$涨超8%，$药明康德(02359)$涨超7%，$三生制药(01530)$、$晶泰控股(02228)$涨超6%，$歌礼制药-B(01672)$涨超4%，$复星医药(02196)$、$云顶新耀(01952)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d9a285c5d35960016c392e2c485f56f0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1046422090.SGD","BK1161","LU0708995583.HKD","02359","LU0320764599.SGD","LU0052750758.USD","02196","02228","BK1515","BK1141","BK1583","HK0000165453.HKD","LU2125910500.SGD","LU2045819591.USD","06978","BK1617","02157","LU2242644610.SGD","BK1576","01672","01952","01477","01530","BK1593","BK1574"],"gpt_icon":0},{"id":"2603147526","title":"复星凯瑞自体双靶点CAR疗法获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2603147526","media":"DoNews","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603147526?lang=zh_cn&edition=full","pubTime":"2026-01-12 21:13","pubTimestamp":1768223582,"startTime":"0","endTime":"0","summary":"复星凯瑞自主研发的自体双靶点CAR-T细胞治疗产品FKC889已获得国家药品监督管理局批准，进入临床试验阶段。该产品针对复发或难治性非霍奇金淋巴瘤，采用双靶点设计以增强对肿瘤细胞的识别和杀伤能力。FKC889的临床试验将评估其在目标患者群体中的安全性、耐受性及初步疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112211618a711c875&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112211618a711c875&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1191","BK1593","BK1515"],"gpt_icon":0},{"id":"2603699544","title":"每日卖空追踪 | 复星医药 01月12日卖空量成交2.9万股，卖空比例为0.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603699544","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603699544?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:30","pubTimestamp":1768206626,"startTime":"0","endTime":"0","summary":"复星医药北京时间01月12日，涨0.86%，卖空量成交2.9万股，较上一交易日减少91.99%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112164844a710c91d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112164844a710c91d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1515","BK1593","BK1191"],"gpt_icon":0},{"id":"2602596084","title":"复星雅立峰冻干人用狂犬病疫苗（Vero细胞）启动IV期临床 适应症为预防狂犬病","url":"https://stock-news.laohu8.com/highlight/detail?id=2602596084","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602596084?lang=zh_cn&edition=full","pubTime":"2026-01-12 12:03","pubTimestamp":1768190580,"startTime":"0","endTime":"0","summary":"本次试验主要目的是评价冻干人用狂犬病疫苗以4剂和5剂基础免疫程序接种于10 - 60周岁人群的免疫持久性和2剂加强免疫的免疫原性、安全性。冻干人用狂犬病疫苗为生物制品，适应症为预防狂犬病。狂犬病是由狂犬病毒引起的急性传染病，主要通过动物咬伤传播。发病后会出现恐水、怕风、咽肌痉挛等症状，病死率接近100%，主要依据动物咬伤史和临床症状诊断。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112130745a4b92965&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112130745a4b92965&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","00656","BK1230"],"gpt_icon":0},{"id":"2602564661","title":"2026机器人“赴港潮”深度透视：投资逻辑全梳理","url":"https://stock-news.laohu8.com/highlight/detail?id=2602564661","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602564661?lang=zh_cn&edition=full","pubTime":"2026-01-12 10:16","pubTimestamp":1768184207,"startTime":"0","endTime":"0","summary":"工业机器人本体赛道中，越疆、珞石机器人是核心代表，越疆的协作机器人出货量位居全球前二，2025年推出新一代高负载协作机器人，珞石机器人的SCARA机器人国产化率高，性价比优势显著。人形与具形机器人本体赛道是当前资本焦点，优必选在人形机器人商业化领域处于领先地位，2025年交付超500台Walker S2，2026年产能目标直指万台级，卧安机器人作为“AI具身家庭机器人第一股”，产品矩阵丰富，上市获两百多倍超额认购，首日股价实现上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1767936709271749765","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["02727","03898","600580","02196","02590","00564","06690","BK1205","LU1152091754.HKD","BK1179","LU0348767384.USD","02675","AMR","LU1655091616.SGD","LU2778985437.USD","BK0224","03750","06613","02432","00699","02670","LU0890818403.SGD","BK1607","BK1610","00300","BK1594","LU0082770016.USD","02498","LU0868486357.SGD","SG9999002950.SGD","09880","CSR","01157","06600","BK1170","BK4215","LU2488822045.USD","BK1214","02228","BK1505","BK4585","IE00BPRC5H50.USD","02252","LU0877626530.USD","LU0431992006.USD","00179","688169","SG9999014674.SGD"],"gpt_icon":1},{"id":"2602535834","title":"每周股票复盘：复星医药（600196）参投基金完成备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2602535834","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602535834?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:14","pubTimestamp":1768068851,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，复星医药报收于27.65元，较上周的26.49元上涨4.38%。本周，复星医药1月9日盘中最高价报27.75元。本周关注点公司公告汇总：复星医药参与投资的华润（成都）医药产业股权投资基金已完成备案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK1515","BK0196","BK1191","BK0175","BK0183","BK0012","BK0028","BK1593","02196","BK0187","BK0096","BK0188","600196"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":-0.0498},{"period":"1month","weight":-0.0241},{"period":"3month","weight":-0.1438},{"period":"6month","weight":0.0755},{"period":"1year","weight":0.5825},{"period":"ytd","weight":0.0353}],"compareEarnings":[{"period":"1week","weight":-0.0109},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.018},{"period":"6month","weight":0.0489},{"period":"1year","weight":0.3464},{"period":"ytd","weight":0.039}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊断分部主要从事分子诊断、免疫诊断、微生物诊断等医疗美容器械的制造和销售。医疗健康服务分部主要从事线上线下一体化医疗服务平台的经营。医药分销和零售分部主要从事医药产品的批发零售。其他分部从事其他医药相关业务。该公司的产品主要用于肿瘤、免疫、中枢神经等治疗领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.04515},{"month":2,"riseRate":0.769231,"avgChangeRate":0.040467},{"month":3,"riseRate":0.615385,"avgChangeRate":0.048431},{"month":4,"riseRate":0.384615,"avgChangeRate":0.03076},{"month":5,"riseRate":0.461538,"avgChangeRate":0.035265},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.026545},{"month":7,"riseRate":0.615385,"avgChangeRate":0.027595},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.041651},{"month":9,"riseRate":0.461538,"avgChangeRate":0.011609},{"month":10,"riseRate":0.461538,"avgChangeRate":0.020359},{"month":11,"riseRate":0.428571,"avgChangeRate":0.034495},{"month":12,"riseRate":0.428571,"avgChangeRate":0.015123}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}